Neoleukin Therapeutics (NASDAQ:NLTX) stock observed trading -29.25% off 52-week high price. On the other end, the stock has been noted 342.92% away from low price over the last 52-weeks. The stock disclosed a move of -12.44% away from 50 day moving average and 88.79% away from 200 day moving average. Moving closer, we can see that shares have been trading -17.01% off 20-day moving average. It has market cap of $494.02M.
On Feb. 25, 2020, Neoleukin Therapeutics (NASDAQ:NLTX) a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, notified the appointment of Robert Ho as Chief Financial Officer, effective March 16, 2020. Kamran Alam, interim CFO of Neoleukin Therapeutics, will continue as a senior strategic advisor to assist in transition activities.
Bob’s deep experience in multiple facets of financial leadership at public companies and financial institutions, including large-scale operations, public offerings, and transactions, will be a great asset to Neoleukin Therapeutics, and we are very pleased to have him join our leadership team, said Jonathan Drachman, M.D., Chief Executive Officer. We have been extremely fortunate to have Kam’s guidance these past months after the merger of the two companies. His knowledge and insights have been invaluable, and we wish him well in his future endeavors.
Mr. Ho brings two decades of financial experience to Neoleukin. He is a former Vice President in the Investment Banking Division of Morgan Stanley & Co., where he managed over $9 billion in financing deals and participated in the completion of more than $5 billion in M&A transactions. Prior to Morgan Stanley, he was an associate in the Healthcare Investment Banking Division at Merrill Lynch & Co. Most recently, Mr. Ho served as Senior Finance Director at DaVita a publicly held, Fortune 500® company that is a leading provider of kidney care services in the U.S. He received his Bachelor of Business Administration from the University of Notre Dame and his MBA from the University of Virginia Darden School of Business.
The USA based company Neoleukin Therapeutics moved with change of -4.53% to $9.7 with the total traded volume of 256337 shares in recent session versus to an average volume of 627.35K shares. The stock was observed in the 5 days activity at -5.55%. The one month performance of stock was -14.46%. NLTX’s shares are at 88.72% for the quarter and driving a 267.42% return over the course of the past year and is now at -21.27% since this point in 2018. Right now the stock beta is -6.05. The average volatility for the week and month was at 7.73% and 7.28% respectively. There are 50.93M shares outstanding and 39.62M shares are floated in market.